Garzon et al. identified a small subset of lncRNAs strongly correlated with the treatment response and survival of elderly patients (>60-year-old) with cytogenetically normal, untreated AML harboring FLT3-ITD, NPM1, CEBPA, IGD2, and RUNX1 mutations [117]. This evidence concerns the gene NPM1 and acute myeloid leukemia.